QuidelOrtho (QDEL) AI Stock Analysis

• Market Cap: $1.34B
• Dividend Yield: N/A
• Average Volume (3M): 1.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.26
• Revenue Growth: -3.43%
• EPS Growth: 38.98%
• Country: US
• Employees: 6,600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.80
• Shares Outstanding: 67,931,540
• 10 Day Avg. Volume: 2,033,521
• 30 Day Avg. Volume: 1,496,836
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.99
• Price to Sales (P/S): 1.06
• P/FCF Ratio: -26.38
• Enterprise Value/Market Cap: 3.49
• Enterprise Value/Revenue: 2.33
• Enterprise Value/Gross Profit: 3.82
• Enterprise Value/Ebitda: -8.79
• 1Y Price Target: $34.60
• Price Target Upside: 58.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): 2.14
• Revenue Forecast (FY): $2.71B

• Rating: 49 Neutral
• Price Target: $22.00 ▲(0.50% Upside)

QuidelOrtho's overall stock score is primarily impacted by its financial performance challenges, including declining revenues and negative profitability. Technical analysis indicates a bearish trend, further weighing on the score. While the earnings call provided some positive insights into cost savings and regional growth, the valuation remains unattractive due to negative earnings and lack of dividends.

Positive Factors

Organic Sales Growth

The company's ability to achieve organic sales growth indicates a strong underlying demand for its core products, suggesting resilience and potential for sustainable revenue expansion.

Cost Savings and Margin Improvement

Significant cost savings and improved EBITDA margins reflect effective cost management, enhancing profitability and providing a buffer against market volatility.

FDA Clearance for New Assay

FDA clearance for new diagnostic assays strengthens the product portfolio, enhancing competitive positioning and opening new revenue streams in cardiac diagnostics.

Negative Factors

Declining Revenue

A decline in revenue, especially from COVID-related products, indicates challenges in maintaining growth, potentially impacting long-term financial stability.

Goodwill Impairment Charge

The substantial goodwill impairment suggests overvaluation of past acquisitions, impacting balance sheet health and indicating potential strategic missteps.

Negative Free Cash Flow

Negative free cash flow highlights cash management issues, which can strain liquidity and limit the company's ability to invest in growth opportunities.

QuidelOrtho Business Overview & Revenue Model

Company Description

QuidelOrtho Corporation is a leading provider of diagnostic solutions, specializing in medical devices and innovative technologies that enhance patient care. The company operates primarily in the infectious disease, women's health, and respiratory sectors, offering a range of products that include rapid diagnostic tests, assays, and molecular diagnostic systems. QuidelOrtho's core mission is to empower healthcare providers with tools that facilitate timely and accurate diagnoses, thereby improving patient outcomes across various healthcare settings.

How the Company Makes Money

QuidelOrtho generates revenue through multiple key streams, primarily from the sale of its diagnostic products, including rapid tests and laboratory systems. The company's revenue model is built on a combination of direct product sales, recurring revenue from test kits and assays, and partnerships with healthcare providers and distributors. QuidelOrtho also benefits from long-term contracts with hospitals and clinics, which provide a stable income base. Collaborations with research institutions and healthcare organizations further enhance its earnings potential, enabling the development of novel diagnostic solutions and expanding its market reach. Additionally, government contracts, particularly during public health emergencies, can significantly boost revenue through increased demand for diagnostic testing.

QuidelOrtho Financial Statement Overview

Summary

QuidelOrtho faces significant financial challenges, with declining revenues, negative profitability, and fluctuating cash flows. While the balance sheet shows balanced leverage, the negative return on equity and operational inefficiencies are concerning. The company needs to address its revenue decline and improve operational efficiency to stabilize its financial position.

Income Statement

QuidelOrtho's income statement shows significant challenges, with declining revenue and negative profit margins. The TTM data reveals a substantial revenue drop of 76.7% and a negative net profit margin of -17.0%. Historical data indicates a consistent decline in revenue growth and profitability, with EBIT and EBITDA margins turning negative in recent periods. These trends highlight operational inefficiencies and market challenges.

Balance Sheet

The balance sheet reflects a stable debt-to-equity ratio of 1.0 in the TTM period, indicating balanced leverage. However, the return on equity is negative, suggesting inefficiencies in generating returns from equity. The equity ratio remains reasonable, but the declining equity and increasing debt levels pose potential risks to financial stability.

Cash Flow

Cash flow analysis shows improvement in free cash flow growth in the TTM period, with a significant increase of 305.6%. The operating cash flow to net income ratio is positive, indicating some operational cash generation despite net losses. However, historical fluctuations in free cash flow and negative free cash flow in previous periods highlight volatility in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	2.01B	2.78B	3.00B	1.70B	1.66B	534.89M
Gross Profit	1.22B	1.29B	1.49B	1.28B	1.35B	320.81M
EBITDA	-531.30M	-1.49B	607.00M	953.30M	1.10B	139.79M
Net Income	-1.00B	-2.05B	-10.10M	704.20M	810.29M	72.92M
Balance Sheet
Total Assets	5.68B	6.42B	8.56B	2.43B	1.87B	910.87M
Cash, Cash Equivalents and Short-Term Investments	98.10M	98.30M	167.30M	828.50M	489.94M	52.77M
Total Debt	2.84B	2.68B	2.61B	139.30M	108.50M	112.30M
Total Liabilities	3.64B	3.44B	3.56B	501.00M	538.46M	351.05M
Stockholders Equity	2.04B	2.98B	5.01B	1.93B	1.33B	559.82M
Cash Flow
Free Cash Flow	-22.30M	-112.10M	70.90M	513.14M	564.84M	107.26M
Operating Cash Flow	-26.70M	83.00M	280.20M	805.87M	629.76M	134.49M
Investing Cash Flow	-143.10M	-149.90M	-187.60M	-319.53M	-63.32M	-27.23M
Financing Cash Flow	166.90M	48.80M	-265.80M	-173.18M	-130.28M	-98.28M

QuidelOrtho Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QDEL, the sentiment is Negative. The current price of 21.89 is below the 20-day moving average (MA) of 26.88, below the 50-day MA of 27.83, and below the 200-day MA of 30.72, indicating a bearish trend. The MACD of -1.75 indicates Positive momentum. The RSI at 34.62 is Neutral, neither overbought nor oversold. The STOCH value of 10.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QDEL.

QuidelOrtho Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HAE	70 Outperform	$3.30B	20.93	19.47%	―	-2.45%	41.50%
HOLX	69 Neutral	$16.54B	30.04	11.12%	―	1.74%	-25.29%
MASI	56 Neutral	$7.69B	―	-17.93%	―	-16.03%	-813.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	50 Neutral	$1.36B	―	-24.65%	―	-32.42%	-540.37%
QDEL	49 Neutral	$1.34B	―	-44.21%	―	-3.43%	38.98%
BAX	40 Neutral	$9.25B	―	-4.70%	3.73%	-21.20%	-325.40%

QuidelOrtho Corporate Events

QuidelOrtho Reports Strong Q3 2025 Financial Results

QuidelOrtho Corporation reported its third-quarter 2025 financial results, highlighting significant improvements in operational performance and cost savings of over $140 million since early 2024. The company achieved a 180 basis point increase in adjusted EBITDA margin to 25% and a 7% reduction in non-GAAP operating expenses year-over-year. Revenue for the quarter reached $700 million, with a 5% growth excluding COVID-19 and Donor Screening. The company also announced the FDA clearance of its VITROS High Sensitivity Troponin assay, enhancing its cardiac testing capabilities. Additionally, QuidelOrtho completed debt refinancing to improve financial flexibility and continued its site consolidation plan, expecting $20 million in annual savings. Despite macroeconomic pressures, the company remains on track to achieve its 2025 financial goals, with a strong outlook for profitability and growth.

The most recent analyst rating on (QDEL) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.

QuidelOrtho’s Strategic Growth Amidst Challenges

QuidelOrtho Corporation’s recent earnings call painted a picture of resilience and strategic growth amidst a challenging landscape. The company demonstrated robust performance in organic sales growth and cost savings, despite facing headwinds from declining COVID and donor screening revenues, negative cash flow due to system conversion, and a substantial goodwill impairment charge.

QuidelOrtho Corporation Reports Q3 2025 Financial Results

QuidelOrtho Corporation, a leader in in vitro diagnostics, provides diagnostic solutions across clinical chemistry, immunoassay, immunohematology, and molecular testing sectors, aiming to improve patient outcomes through innovative technology.

QuidelOrtho Completes Major Debt Refinancing Transaction

On August 21, 2025, QuidelOrtho Corporation completed a significant debt refinancing transaction, entering into a Credit Agreement with Bank of America and other lenders. This agreement includes a $1.15 billion senior secured term loan A, a $100 million delayed draw term loan A, a $1.45 billion senior secured term loan B, and a $700 million revolving credit facility. The refinancing allows QuidelOrtho to extend its debt maturities, reduce required amortization payments, and improve financial flexibility, supporting future growth and strengthening its capital structure.

The most recent analyst rating on (QDEL) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.